-
Mashup Score: 6
PURPOSEAfter radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 63
PURPOSETransurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether definitive treatment can be …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial | Journal of Clinical Oncology https://t.co/z87ZuNjwjw @JCO_ASCO @ASCO @Prof_Nick_James
-
-
Mashup Score: 1
muscle-invasive bladder cancer (MIBC), PURE-01 trial, immune checkpoint inhibitor (ICI), BLASST-1 trial, NIAGARA trial, KEYNOTE-866 trial, Pembrolizumab, Distinct Gene Expression Patterns, PD-L1 inhibition, GUSTO trial, KRT20, cT2-4N0M0, H19, CXCL11, CC5.
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet-
RT @Davicioni: https://t.co/m13TytLvrp via @urotoday
-
-
Mashup Score: 40
PARP inhibitors are a very effective treatment option for metastatic castration-resistant prostate cancer. Although rare cardiovascular and thromboembolic toxicity is rare, there is a risk of high-grade adverse events with PARP inhibitors in comparison to other treatments in this setting.
Categories: General Medicine News, Hem/OncsTweet-
PARP inhibitors Cv safety in full @BrigidaMaiorano @vale_tateo @Anto_cigliola @CMercinelli @MyUniSR @SanRaffaeleMI @neerajaiims @shilpaonc @EurUrolOpen @Uroweb https://t.co/CBsRoDKBRr
-
-
Mashup Score: 7The Italian health data system is broken - 2 month(s) ago
The population of Italy is projected to decrease by approximately 8% by 2050, falling from 59 million in 2022 to 54.4 million, due to increased ageing and a declining birth rate. By 2050, more than 35% of Italians will be older than 65 years, while children younger than 14 years will represent only 11.7% of the population. Without reforms, this demographic shift will strain health-care and social systems.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
The Italian health data system is broken - The Lancet Regional Health – Europe https://t.co/fnbBNSVPgf
-
-
Mashup Score: 59
PURPOSETransurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether definitive treatment can be …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial | Journal of Clinical Oncology https://t.co/z87ZuNjwjw @JCO_ASCO @ASCO @Prof_Nick_James
-
-
Mashup Score: 7The Italian health data system is broken - 2 month(s) ago
The population of Italy is projected to decrease by approximately 8% by 2050, falling from 59 million in 2022 to 54.4 million, due to increased ageing and a declining birth rate. By 2050, more than 35% of Italians will be older than 65 years, while children younger than 14 years will represent only 11.7% of the population. Without reforms, this demographic shift will strain health-care and social systems.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
The Italian health data system is broken - The Lancet Regional Health – Europe https://t.co/fnbBNSVPgf
-
-
Mashup Score: 7The Italian health data system is broken - 2 month(s) ago
The population of Italy is projected to decrease by approximately 8% by 2050, falling from 59 million in 2022 to 54.4 million, due to increased ageing and a declining birth rate. By 2050, more than 35% of Italians will be older than 65 years, while children younger than 14 years will represent only 11.7% of the population. Without reforms, this demographic shift will strain health-care and social systems.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
The Italian health data system is broken - The Lancet Regional Health – Europe https://t.co/fnbBNSVPgf
-
-
Mashup Score: 27The Financial Burden of Localized and Metastatic Bladder Cancer - 2 month(s) ago
Bladder cancer treatment, especially for muscle-invasive and metastatic disease, is costly. Financial toxicity of bladder cancer is prevalent among younger patients and minorities. Research should prioritize the economic impact of new therapies to improve outcomes without increasing financial burdens on patients and health care systems.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
The Financial Burden of Localized and Metastatic Bladder Cancer - European Urology https://t.co/m2yG1pTIka
-
-
Mashup Score: 27The Financial Burden of Localized and Metastatic Bladder Cancer - 3 month(s) ago
Bladder cancer treatment, especially for muscle-invasive and metastatic disease, is costly. Financial toxicity of bladder cancer is prevalent among younger patients and minorities. Research should prioritize the economic impact of new therapies to improve outcomes without increasing financial burdens on patients and health care systems.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
The Financial Burden of Localized and Metastatic Bladder Cancer - European Urology https://t.co/m2yG1pTIka
-
Happy to share the first @JCO_ASCO simultaneous publication of the year @ASCO #GU25 https://t.co/92srwxGMDD